Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.15 per share a year ago ...

Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ...

As Medtronic and Axonics’ legal battle over alleged similarities between their sacral neuromodulation devices drags on, Medtronic is getting the U.S. International Trade Commission involved. The ...

A federal jury in California has found that Axonics’ neurostimulators and electric leads for treating incontinence do not run afoul of three patents held by the company’s main rival, Medtronic. The ...

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...